Endocyte, Inc. (NASDAQ:ECYT)
| CAPS Rating |
|
|---|
ECYT
VS S&P 500 (SPY)
ECYT News and Commentary
- MannKind Rents Out a Drug Program – The Motley Fool
- Applications Given Early Antitrust Clearance – SmartMoney
- 2nd UPDATE: Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows – SmartMoney
- 5 of Last Week's Biggest Winners – The Motley Fool
- Stocks Shaking the Investment World – The Motley Fool
- Merck in Oncology Deal - Analyst Blog – NASDAQ
- Merck Updates: Partners With Endocyte; Propecia Gets New Virility Warnings – Trefis
- Company News for April 17, 2012 - Corporate Summary – NASDAQ
- Pre-Market Most Active for Apr 17, 2012 : BAC, NOK, MT, STWD, GS, QQQ, SAP, SIRI, AAPL, FSLR, ECYT, – NASDAQ
How do you think ECYT will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
51
Outperform
4
Underperform
All-Star Players
13
Outperform
2
Underperform
Wall Street
3
Outperform
0
Underperform
RSS Headlines
Fool UK
